نتائج البحث

Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment.

• Authors : Kawczak, Piotr¹ (AUTHOR) ; Feszak, Igor Jarosław² (AUTHOR); Bączek, Tomasz^1,3 (AUTHOR)

• Source: Journal of Clinical Medicine. Mar2025, Vol. 14 Issue 6, p2107. 22p.

تفاصيل العنوان

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

• Source: A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid

تفاصيل العنوان

Biologic Disease-Modifying Antirheumatic Drugs for Preventing Radiographic Progression in Psoriatic Arthritis: A Systematic Review and Network Meta-Analysis.

• Authors : Wang, Szu-Hsuan¹ (AUTHOR); Yu, Chia-Ling¹ (AUTHOR); Wang, Tzu-Yu² (AUTHOR)

• Source: Pharmaceutics. Oct2022, Vol. 14 Issue 10, pN.PAG-N.PAG. 14p.

تفاصيل العنوان

Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study

• Authors : Teresa A Simon; Samy Suissa; Maarten Boers

Subjects: Abatacept; Arthritis, Rheumatoid; Marketing

• Source: Simon, T A, Suissa, S, Boers, M, Hochberg, M C, Skovron, M L, Askling, J, Michaud, K, Strangfeld, A, Pedro, S, Frisell, T, Meissner, Y, Dominique, A & Gomez, A 2024, ' Malignancy outcomes in patients

تفاصيل العنوان

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry

• Authors : Akio Kawabe; Kazuhisa Nakano; Satoshi Kubo

Subjects: Inverse probability of treatment weighting; Generalized propensity score; Tumor Necrosis Factor-alpha

• Source: Arthritis Res TherArthritis Research & Therapy, Vol 22, Iss 1, Pp 1-12 (2020)

تفاصيل العنوان

Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial

• Authors : Martin Bergman; Namita Tundia; Naomi Martin

Subjects: Biological Products; Patient-reported outcomes; JAK inhibitors

• Source: Arthritis Res TherArthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)

تفاصيل العنوان

Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic

• Authors : Umut KALYONCU; Yavuz PEHLİVAN; Servet AKAR ...

Subjects: rheumatoid arthritis; Male; Bath ankylosing spondylitis disease activity index

• Source: Turk J Med SciTurkish Journal of Medical Sciences

تفاصيل العنوان

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice

• Authors : Viking Huss; Hannah Bower; Hjalmar Wadström

Subjects: Biological Products; Clinical Science; 3. Good health

• Source: Rheumatology (Oxford)

تفاصيل العنوان

Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis

• Authors : Cristina, Martínez-Múgica; Esther, Salgueiro

Subjects: Abatacept; Arthritis, Rheumatoid; Male

• Source: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria. 46(1)

تفاصيل العنوان

Incidence of Interstitial Lung Disease in Patients With Rheumatoid Arthritis Treated With Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs

• Authors : Baker, Matthew C.; Liu, Yuhan; Lu, Rong

Subjects: Adult; Biological Products; Incidence

• Source: JAMA Netw Open

تفاصيل العنوان